The AI scribe became healthcare’s default purchase
Over the last three years, AI medical scribes became one of the most common technology purchases in healthcare, and the logic held up. Documentation was the most visible driver of clinician burnout, and ambient clinical documentation offered immediate, demonstrable relief.
Physicians could face the patient again while the note assembled itself in the background. For a problem everyone in the building could feel, the AI scribe was a clear and defensible answer. The category grew quickly, funding followed, and most large health systems now run ambient documentation in some form. That success is real, and it is worth understanding precisely, because it points to where the next healthcare AI investment should go.
What the JAMA scribe study actually found
In April 2026, JAMA published the largest multi-site study of ambient AI scribes to date. Rotenstein and colleagues followed 8,581 ambulatory clinicians across five academic health systems, 1,809 of them active scribe users, on platforms from Ambience, Nuance DAX Copilot, and Abridge. The findings were consistent and carefully measured. Scribes reduced documentation time by about sixteen minutes per eight scheduled patient hours, lowered total EHR time by roughly thirteen minutes, and added close to half a visit per clinician each week. These are genuine improvements in documentation burden and clinician experience, and they are also bounded. The study put a number on something the market had sensed but not yet stated plainly, which is that the value of an AI scribe is the value of capture.
Capture has a ceiling
Once the conversation is transcribed and the note is structured, the AI scribe has finished its work. Capturing what was said in the exam room is a genuinely different task from understanding what to do with it. A clean, well-formed note is necessary, and it is the same thing as a defensible clinical and financial decision only in the rarest cases. This is the natural limit of ambient documentation. It records the encounter faithfully, and it does not reason about whether that encounter will hold up to a payer, a quality program, or an audit. Every scribe vendor runs into the same ceiling, because the ceiling belongs to documentation itself. A health system can deploy the best-rated scribe on the market and still face the same claim denials, the same medical necessity gaps, and the same after-hours review, because none of those were documentation problems to begin with.
The hard problems live one layer up
The difficult work in healthcare sits above transcription. A scribe-generated note still has to survive a payer. It has to defend medical necessity, justify an admission, align to the correct codes, and connect to whatever care comes next. None of that is documentation, and all of it is reasoning. When a claim is denied, the scribe does not weigh the appeal. When an admission is questioned, the scribe does not test it against the rubric. When the same condition carries different requirements under different contracts, the scribe does not adjust. The captured record sits there, accurate and inert, waiting for something to reason over it. This is where claim denials originate, and where revenue cycle teams spend their days on rework that stronger upstream reasoning would have prevented.
cliexa is the reasoning layer above the scribe
cliexa occupies that layer. The clinical reasoning layer of healthcare. Whatever AI scribe a health system has chosen, the cliexaAI clinical intelligence platform works on top of it, scribe-agnostic and EMR-agnostic. The scribe captures the encounter, and cliexa determines whether what was captured is clinically and financially defensible, what the payer will require before the visit rather than after the denial, and what the next clinical step should be. The way it reasons is what sets this clinical AI apart from the documentation layer beneath it.
cliexa works from the outside in. It starts with payer intelligence, the contracts and adjudication rules that decide whether care is actually reimbursed, then applies the provider and entity protocols that govern quality, then personalizes both to the patient’s real-time state at the point of care.
Where the next decade of value sits
Payer reality becomes a clinical input at the front of the encounter instead of a billing cleanup task at the end of it, which is the foundation of real denial prevention.
The system then learns from every outcome, reinforcing the patterns that get approved and correcting the ones that get denied, so the clinical reasoning sharpens with each cycle. This is deliberately complementary to the scribe market. The scribe vendors are very good at what they do, and choosing among them is a decision each health system should make on its own EHR and its own terms. cliexa operates on the output, turning a captured record into a defensible decision. The scribe era solved capture. The value that remains sits one layer up, in the reasoning that converts a record into sound clinical and financial action, and cliexa is built for that layer.
Already invested in a scribe? Keep it.
cliexa works on top of whatever you’ve chosen. Scribe-agnostic, EMR-agnostic.